| 姓名:Lavern |  | 188.143.232.** | | 時間:2015/5/21 上午 06:04:54 | | ☆☆☆☆☆ | | Hello good day <a href=" http://www.7pennies.com/tadalista-chewable/ ">tadalista pills</a> Merck, which already markets the HCV treatment Victrelis (boceprevir), was granted BTD in April for lambrolizumab, its much-touted investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for advanced mela***ma. R&D chief Roger Perlmutter ***ted that "there remains significant unmet medical need in hepatitis C, and we are looking forward to working with the FDA to advance this programme as quickly as we can".
| |